Growth hormone is released by the pituitary in pulses, guided by signals from the brain. Sermorelin copies one of those signals. That makes it different from taking growth hormone itself, and it is why its history and evidence are worth understanding before anyone considers it.
Key points
- Sermorelin is a copy of the first 29 amino acids of growth hormone releasing hormone (GHRH).
- It was FDA-approved as Geref, then discontinued in 2008; FDA later found this was not for safety or effectiveness reasons.
- No FDA-approved sermorelin product is on the market today.
- It prompts the pituitary to release its own growth hormone rather than replacing it.
- Adult studies are small and short and do not establish long-term benefits.
Where things stand (as of November 2026)
Sermorelin is a lab-made copy of the first 29 amino acids of growth hormone releasing hormone (GHRH). It was FDA-approved as Geref, in 1990 for testing pituitary function and in 1997 for growth hormone deficiency in children.
The maker stopped selling it in 2008, and FDA withdrew the approvals in 2009. In 2013 FDA determined Geref was not withdrawn for reasons of safety or effectiveness.
No FDA-approved sermorelin product is on the market today. Some pharmacies compound it; whether and how it can be compounded depends on current federal rules, which we review at your visit. A compounded product is not equivalent to the former approved Geref.
How it works
Sermorelin signals the pituitary to release its own growth hormone in pulses, rather than replacing growth hormone directly. The body's own feedback, through somatostatin and IGF-1, still applies, which limits how far levels rise.
What the evidence shows
The strongest data come from its approved use in children with growth hormone deficiency.
Studies in adults are small and short. They show rises in growth hormone and IGF-1 but do not establish long-term benefits for aging, body composition or performance.
Safety
Injection site reactions, flushing and headache were reported with Geref. It is not a fit for everyone, for example people with active cancer. A physician review of labs and history comes first.
Common questions
Is sermorelin FDA-approved?
No longer. Sermorelin was approved as Geref and later discontinued by its maker. In 2013 FDA determined it was not withdrawn for reasons of safety or effectiveness. No FDA-approved sermorelin product is sold today.
Is sermorelin the same as growth hormone?
No. Sermorelin is a signal that prompts the pituitary to release its own growth hormone. Growth hormone medicines replace the hormone directly.
What does the research show for adults?
Small, short studies show that sermorelin raises growth hormone and IGF-1 levels. They do not establish long-term benefits for aging, body composition or performance.
Who should not use sermorelin?
It is not a fit for everyone, for example people with active cancer. Pregnancy, other medical conditions and current medicines also matter, so a physician review of your labs and history comes first.
Is sermorelin available at Institute of Function?
Availability depends on current federal rules; we review options at your visit. A physician assessment covers your history, labs, the evidence and the risks, and prescribing is never guaranteed.
What this means for patients
- Sermorelin works through the body's own growth hormone system rather than replacing the hormone.
- Its adult evidence is early, so any decision starts with a physician assessment.
What this does not mean
- It does not mean sermorelin is a proven anti-aging or performance treatment.
- A compounded product is not equivalent to the former approved Geref.
Sources
- Federal Register, 78 FR 14095, March 4, 2013: Determination That GEREF (Sermorelin Acetate) Injection Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
FDA's determination that Geref was not withdrawn from sale for reasons of safety or effectiveness.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.
A commentary on sermorelin's mechanism and the limited adult evidence.
Many peptide-based therapies remain investigational for musculoskeletal pain, recovery, and performance applications. Available evidence varies by compound, indication, and route of administration. Treatment decisions require physician evaluation, informed consent, and compliance with applicable law.
Want to understand whether this applies to you?
Request a Private AssessmentHave imaging, labs, or prior treatment records?
Request a Private Assessment